Skip to main content

Table 1 Baseline characteristics of patients in the Australian IPF Registry

From: Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry

Variable n overall Mild (FVC ≥ 80%) Moderate-Severe (FVC < 80%) Pa Min Max
216 200
Age, years 416 70.4 (8.6) 71.6 (7.9) 69.0 (9.1) 0.003 31.5 89.9
Male, n (%) 416 290 (69.7%) 125 (57.9%) 165 (82.5%) <0.001   
Ever smoker, n (%) 416 308 (74.0%) 160 (74%) 148 (74%) 0.986   
BMI, kg/m2 412 28.8 (4.8) 28.9 (5.0) 28.6 (4.6) 0.565 15.8 46.4
FVC, L 416 2.6 (0.8) 2.96 (0.79) 2.30 (0.54) <0.001 0.9 4.8
FVC, % pred 416 81.7 (21.2) 97.3 (16.6) 64.9 (9.8) <0.001 40.9 219.5
FEV1/FVC ratio% 416 82.2 (8.4) 80.1 (8.6) 84.4 (7.5) <0.001 27.0 135.0
DLco, % pred 416 48.5 (16.8) 54.6 (17.4) 41.8 (13.2) <0.001 9.4% 143.7%
CPI 416 45.1 (14.1) 37.5 (13.2) 53.3 (9.7) <0.001 54.2 74.5
GAP stage 416     <0.001   
GAP stage 1   192 (46.2%) 152 (70.4%) 40 (20.0%)    
GAP stage 2   186 (44.7%) 64 (29.6%) 122 (61.0%)    
GAP stage 3   38 (9.1%) 0 (0%) 38 (19.0%)    
6MWT distance, m 164 431.0 (119) 433 (115) 430 (122) 0.894 48.0 706.0
Initial SpO2, % 163 95.5 (3.19) 95.8 (3.4) 95.4 (3.1) 0.482 83.0 100.0
End SpO2, % 160 86.2 (7.2) 89.0 (7.0) 84.4 (6.8) <0.001 58.0 99.0
Nadir SpO2, % 153 85.3 (7.1) 87.9 (7.3) 83.6(6.5) <0.001 58.0 99.0
SGRQ 383 43.0 (19.7) 38.7 (19.0) 47.6 (44.8) <0.001 0.0 96.6
UCSD SOBQ 243 40.8 (29.3) 33.7(27.1) 48.6 (29.6) <0.001 0.0 119.0
Cough severity 347 39.5 (23.5) 36.9 (22.9) 42.3(23.9) 0.034 0.0 100.0
Anti-fibrotic therapy 416 102 (24.5%) 52 (24.1%) 50 (25.0%) 0.826   
  1. acomparison between mild and severe physiological impairment